A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
This study is testing a new, investigational medicine called TYRA-430 for adults with advanced liver cancer and other solid tumors. It is designed for cancers that have specific changes in their genes, known as FGF or FGFR aberrations.
You may be able to join if you are 18 or older, can take pills by mouth, and are well enough to perform daily activities. Your vital organs must be working well, and your cancer should not be curable with standard local treatments like surgery.
Participants will take the investigational study medication, TYRA-430, as a pill by mouth. The study team will closely monitor your health, check for side effects, and see how well the treatment works against your tumor.
This study is currently recruiting participants at locations in Los Angeles, San Francisco, and Stanford, California. It is a Phase 1 study, meaning it is the very first time this medication is being tested in humans.
- 1Tests a new targeted pill called TYRA-430 for advanced solid tumors and liver cancer
- 2Requires specific genetic changes in the FGF/FGFR pathway to qualify
- 3Currently active and recruiting patients at multiple locations in California
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.